Abstract
We have found that mouse ear oedema induced by the topical application of arachidonic acid is not a specific screen for compounds inhibiting the lipoxygenase or cyclo-oxygenase pathways of arachidonic acid metabolism. Although such compounds are able to reduce the oedema substantially, pharmacological agents such as histamine antagonists, phosphodiesterase inhibitors, free radical scavengers, and also various compounds not normally considered to have anti-inflammatory properties, can equally effectively reduce the oedema. A mutual potentiation of the effects of prostaglandins, leukotrienes and mast cell-derived histamine would allow many, but not all, of the active agents to be rationalised. The ability of compounds not influencing these three types of inflammatory mediators to reduce the oedematous response means the model is of limited value for directed screening.
Similar content being viewed by others
Abbreviations
- 5-HETE:
-
5-hydroxyeicosatetraenoic acid
- LTB4 :
-
leukotriene B4
- NDGA:
-
norkihydroguaiaretic acid
- NSAIDs:
-
non-steroidal anti-inflammatory drugs
- NBT:
-
nitroblue tetrazolium chloride
- PG:
-
prostaglandin (E1, A2, etc.)
- THF:
-
tetrahydrofuran
- TxB2 :
-
thromboxane B2
References
S. Hammarström, M. Hamberg, B. Samuelsson, E. A. Duell, M. Stawiski and J. J. Voorhees,Increased concentrations of nonesterified arachidonic acid, 12L-hydroxy-5,8,10,14-eicosatetraenoic acid, prostaglandin E 2 and prostaglandin F 2α in epidermis of psoriasis. Proc. Natl. Acad. Sci. USA72, 5130–5134 (1975).
S. D. Brain, R. Camp, P. Dowd, A. Kobza Black and M. Greaves,The release of leukotriene B 4-like material in biologically active amounts from the lesional skin of patients with psoriasis. J. Invest. Dermatol.83, 70–73 (1984).
R. D. R. Camp,Prostaglandins, hydroxy fatty acids, leukotrienes and inflammation of the skin. Clin. expl. Dermatol.7, 435–444 (1982).
R. Camp, R. Russell Jones, S. Brain, P. Wollard and M. Greaves,Production of intraepidermal microabscesses by topical application of leukoitriene B 4. J. Invest. Dermatol.82, 202–204 (1984).
E. Wong, R. D. Camp and M. W. Greaves,The responses of normal and psoriatic skin to single and multiple topical applications of leukotriene B 4. J. Invest. Dermatol.84, 421–423 (1985).
P. Crunkhorn and A. L. Willis,Cutaneous reactions to intradermal prostaglandins. Br. J. Pharmac.41, 49–56 (1971).
T. J. Williams and M. J. Peck,Role of prostaglandinmediated vasodilatation in inflammation. Nature270, 530–532 (1977).
N. A. Soter, R. A. Lewis, E. J. Corey and K. F. Austen,Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4)in human skin. J. Invest. Dermatol.80, 115–119 (1983).
G. A. Higgs, J. A. Salmon and J. A. Spayne,The inflammatory effects of hydroperoxy and hydroxy acid products of arachidonate lipoxygenase in rabbit skin. Br. J. Pharmac.74, 429–433 (1981).
R. J. Flower, E. A. Harvey and W. P. Kingston,Inflammatory effects of prostaglandin D 2 in rat and human skin. Br. J. Pharmac.56, 229–233 (1976).
M. A. Bray, F. M. Cunningham, A. W. Ford-Hutchison and M. J. H. Smith,Leukotriene B 4:a mediator of vascular permeability. Br. J. Pharmac.72, 483–486 (1981).
A. Ueno, K. Tanaka, M. Katori, M. Hayashi and Y. Arai,Species difference in increased vascular permeability by synthetic leukotriene C4 and D4. Prostaglandins21, 637–648 (1981).
J. M. Young, D. A. Spires, C. J. Bedord, B. Wagner, S. J. Ballaron and L. M. De Young,The mouse ear inflammatory response to topical arachidonic acid. J. Invest. Dermatol.82 367–371 (1984).
E. E. Opas, R. J. Bonney and J. L. Humes,Prostaglandin and leukotriene synthesis in mouse ears inflamed by arachidonic acid. J. Invest. Dermatol.84, 253–256 (1985).
P. Sonnino-Goldman, D. Donigi Ruzza, S. Hyman, E. S. Neiss, T. P. Pruss and P. S. Wolf,Comparative effects of topically applied REV 5901, phenidone and indomethacin on arachidonic acid-induced ear inflammation in DBA/2J mice. Agents and Actions16, 598–599 (1985).
R. P. Carlson, L. O'Neill-Davis, J. Chang and A. J. Lewis,Modulation of mouse ear edema by cyclo-oxygenase and lipoxygenase inhibitors. Agents and Actions16, 599 (1985).
E. C. Arner, B. L. Rule, M. S. Rudnick and W. Galbraith,Arachidonic acid-induced ear edema: correlation of swelling with production of lipoxygenase products. Agents and Actions16, 600–601 (1985).
J. Berkenkopf, C. Casmer and A. Watnick,Drug activities in arachidonic acid and croton oil induced inflammations. Agents and Actions16, 601–602 (1985).
R. P. Carlson, L. O'Neill-Davis, J. Chang and A.J. Lewis,Modulation of mouse ear edema by cyclooxygenase and lipoxygenase inhibitors and other pharmacologic agents. Agents and Actions17, 197–204 (1985).
W. Bors, M. Saran, E. Lengfelder, C. Michel, C. Fuchs and C. Frenzel,Detection of oxygen radicals in biological reactions. Photochemistry and Photobiology28, 629–638 (1978).
D. Lagunoff and E.Y. Chi,Cell biology of mast cells and basophils. InThe cell biology of inflammation (Handbook of Inflammation 2) pp. 216–265 (Ed. G. Weissmann). Elsevier/North-Holland Biomedical Press. Amsterdam 1980.
J. B. Malick, J. B. Patel, A. I. Salama, B. A. Meiners, R. E. Giles and M. E. Goldberg,Tracazolate: a novel nonsedative anxiolytic. Drug Development Res.4, 61–73 (1984).
C. D. Nicholson and R. Wilke,The apparent tissue selectivity of some alkylxanthines as phosphodiesterase inhibitors. Naun. Schmied. Arch. Pharmacol.332 (Suppl. R33 (1986).
J. F. Riley and G. B. West,Histamine liberation in the rat and mouse. Arch. int. Pharmacodyn. CII 304–313 (1955).
R. J. Flower, J. N. Wood and L. Parente,Macrocortin and the mechanism of action of the glucocorticoids. Adv. Infl. Res.7, 61–70 (1984).
S. J. Foster and M. E. McCormick,The mechanism of the anti-inflammatory activity of glucocorticosteroids. Agents and Actions16, 58–59 (1985).
K. Sugio, K. Ohuchi, M. Sugata and S. Tsurufuji,Suppression by dexamethasone of vascular permeability responses induced with leukotrienes C and D in the rat skin. Prostaglandins21, 649–653 (1981).
K. B. Glaser and R. S. Jacobs,Molecular pharmacology of manoalide: inactivation of bee venom phospholipase A 2. Biochem. Pharmacol.35, 449–453 (1986).
W. E. M. Lands,Mechanisms of action of anti-inflammatory drugs. Adv. Drug Res.14, 147–164 (1985).
F. A. Kuehl, J. L. Humes, R. W. Egan, E. A. Ham, G. C. Beveridge and C. G. Van Arman,Role of prostaglandin endoperoxide PGG 2 in inflammatory processes. Nature265, 170–173 (1977).
P. Needleman, A. Raz, M. S. Minkes, J. A. Ferrendelli and H. Sprecher,Triene prostaglandins: prostacyclin and thromboxane biosynthesis and unique biological properties. Proc. Natl. Acad. Sci. USA76, 944–948 (1979).
T. H. Lee, J.-M. Mencia-Huerta, C. Shih, E. J. Corey, R. A. Lewis and K. F. Austen,Characterization and biologic properties of 5,12-dihydroxy derivatives of eicosapentaenoic acid, including leukotriene B 5 and the double lipoxygenase product. J. Biol. Chem.259, 2383–2389 (1984).
W. C. Pickett, C. Dondero and R. McReynolds,Replacement of arachidonic acid with eicosapentaenoic acid attenuates the fatty acid or phorbol myristate acetate induced mouse ear edema. Agents and Actions16, 602 (1985).
R. P. Schleimer, D. W. MacGlashan, E. S. Schulman, S. P. Peters, G. K. Adams, N. F. Adkinson and L. M. Lichtenstein,Human mast cells and basophils-Structure, function, pharmacology and biochemistry. Clin. Rev. Allergy1, 327–341 (1983).
J. Chang, L. O'Neill-Davis, B. Lamb, R. P. Carlson and A. J. Lewis,The utility of arachidonic acid-treated mouse ear inflammatory model as a potential screen for lipoxygenase inhibitors. Agents and Actions16, 600 (1985).
Author information
Authors and Affiliations
Additional information
This report includes work done as part of a Sandwich Degree Course at Aston University.
Rights and permissions
About this article
Cite this article
Crummey, A., Harper, G.P., Boyle, E.A. et al. Inhibition of arachidonic acid-induced ear oedema as a model for assessing topical anti-inflammatory compounds. Agents and Actions 20, 69–76 (1987). https://doi.org/10.1007/BF01965627
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01965627